4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells

Glioblastoma (GBM) is the most frequent malignant primary tumor of the CNS in adults, with a median survival of 14.6 months after diagnosis. The effectiveness of GBM therapies remains poor, highlighting the need for new therapeutic alternatives. In this work, we evaluated the effect of 4-methylumbel...

Descripción completa

Detalles Bibliográficos
Autores principales: Pibuel, Matías A., Poodts, Daniela, Sias, Sofía A., Byrne, Agustín, Hajos, Silvia E., Franco, Paula G., Lompardía, Silvina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249561/
https://www.ncbi.nlm.nih.gov/pubmed/37291120
http://dx.doi.org/10.1038/s41598-023-35045-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249561/
https://www.ncbi.nlm.nih.gov/pubmed/37291120
http://dx.doi.org/10.1038/s41598-023-35045-3

Ejemplares similares